Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Congestive Cardiomyopathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Congestive Cardiomyopathy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-023184-18 Sponsor Protocol Number: C10-44 Start Date*: 2012-01-25
    Sponsor Name:Inserm
    Full Title: PRE clinical mutation CARriers from families with DIlated cardiomyopathy and ACE inhibitors (PRECARDIA-INHERITANCE study) Preventive effect of ACE inhibitor (perindopril) on the onset or progres...
    Medical condition: dilated cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001063-23 Sponsor Protocol Number: 012357 Start Date*: 2018-06-14
    Sponsor Name:Queen Mary Innovation Centre, Queen Mary University of London
    Full Title: PHASE II STUDY ASSESSING THE COMBINED USE OF AUTOLOGOUS BONE MARROW DERIVED MONONUCLEAR CELLS AND G-CSF WITH PERCUTANEOUS CIRCULATORY ASSISTANCE IN THE TREATMENT OF DILATED CARDIOMYOPATHY
    Medical condition: Heart failure is caused by a cardiomyopathy, which is defined as a disorder of the heart muscle. Dilated cardiomyopathy (DCM) is characterised by enlargement of the ventricles and impaired systolic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-009463-61 Sponsor Protocol Number: MD2009.01 Start Date*: 2009-08-06
    Sponsor Name:Sanquin Plasma Products
    Full Title: Controlled trail of immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - - a prospective, double-blind, randomized, placebo-controlled...
    Medical condition: PVB19 mediated cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056419 Dilated cardiomyopathy LLT
    9.1 10034099 Parvovirus B19 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013112-12 Sponsor Protocol Number: REGENERATE/DCM/2.0 Start Date*: 2010-04-22
    Sponsor Name:Barts & the London NHS Trust
    Full Title: Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dila...
    Medical condition: Idiopathic Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    10056419 Dilated Cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022579-68 Sponsor Protocol Number: COR-1/02 Start Date*: 2011-08-16
    Sponsor Name:Corimmun GmbH
    Full Title: COR-1, an anti-ß1 receptor antibody cyclopeptide in heart failure: a phase II, multicentre, randomised, double-blind and placebo-controlled study with parallel groups
    Medical condition: Heart Failure, Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002246-32 Sponsor Protocol Number: DWN.0710.008.2020P Start Date*: 2023-03-08
    Sponsor Name:Krakowski Szpital Specjalistyczny im. Jana Pawla II
    Full Title: Evaluation of myocardial uptake of CardioCell in patients with non-ischaemic heart failure using the CIRCULATE catheter for transcoronary administration of pharmacologic and cell-based agents (CIRC...
    Medical condition: Dilated cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002335-17 Sponsor Protocol Number: 2015-602295-01 Start Date*: 2015-11-30
    Sponsor Name:Ethicare GmbH
    Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN CHILDREN WITH HEART FAILURE DUE TO DILATED CARDIOMYOPATHY
    Medical condition: Heart Failure due to Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002397-21 Sponsor Protocol Number: 2015-602295-03 Start Date*: 2015-11-30
    Sponsor Name:Ethicare GmbH
    Full Title: FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIL
    Medical condition: Heart Failure due to Dilated Cardiomyopathy and Congenital Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10010495 Congenital heart disease NOS LLT
    18.1 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) AT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002015-98 Sponsor Protocol Number: CMMo/MD/2013 Start Date*: 2013-10-21
    Sponsor Name:Fundación Progreso y Salud
    Full Title: Clinical trial phase III multicenter, double-blind, randomized, placebo-controlled trial evaluating the efficacy of intracoronary infusion of autologous adult stem mononuclear bone marrow unexpande...
    Medical condition: dilated cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    14.1 10007541 - Cardiac disorders 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004310-25 Sponsor Protocol Number: ARRAY-797-301 Start Date*: 2018-12-14
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
    Medical condition: Dilated Cardiomyopathy (DCM) with Lamin A/C protein (LMNA) Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NO (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020352-59 Sponsor Protocol Number: GHF112670 Start Date*: 2010-07-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III ...
    Medical condition: NYHA Class II/III congestive heart failure.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004670-25 Sponsor Protocol Number: CQ-001-19 Start Date*: 2022-11-16
    Sponsor Name:Corequest sagl
    Full Title: Peritoneal Ultrafiltration in cardio Renal syndrome to prevent heart failure Exacerbation: The PURE Study
    Medical condition: Congestive Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007559 Cardiac failure congestive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001700-37 Sponsor Protocol Number: CELL-004 Start Date*: 2012-10-03
    Sponsor Name:Celladon Corporation
    Full Title: A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects ...
    Medical condition: Moderate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) BE (Completed) PL (Completed) NL (Completed) DK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-005767-26 Sponsor Protocol Number: 2006-KarviD-II Start Date*: 2007-05-22
    Sponsor Name:The Department of Calcium- and Bone-metabolic Diseases
    Full Title: The effect of calcium and vitamin D on the heartmusclef unction
    Medical condition: Effect of intervention with vitamin D on degree of cardiac incompensation: Degree of cardiac incompensation has been related to vitamin D deficiency and secondary hyperparathyroidism in clinical st...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010684 Congestive heart failure LLT
    9.1 10047626 Vitamin D deficiency LLT
    9.1 10020708 Hyperparathyroidism secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003497-48 Sponsor Protocol Number: EMPATHY Start Date*: 2021-11-29
    Sponsor Name:Medical University of Warsaw
    Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005278-59 Sponsor Protocol Number: 20050222 Start Date*: 2006-12-22
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symp...
    Medical condition: Heart Failure Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007559 Cardiac failure congestive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) LT (Completed) SK (Completed) BE (Completed) EE (Completed) FI (Completed) HU (Completed) DK (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) AT (Completed) PT (Completed) NL (Completed) LV (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001117-13 Sponsor Protocol Number: C3BS-C-11-01 Start Date*: 2012-11-14
    Sponsor Name:Celyad SA
    Full Title: Efficacy and Safety of Bone Marrow-Derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure
    Medical condition: Chronic advanced symptomatic heart failure secondary to ischemic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) PL (Completed) SE (Completed) ES (Completed) IE (Completed) BG (Completed) LT (Completed) EE (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002465-35 Sponsor Protocol Number: B3461028 Start Date*: 2014-04-07
    Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company
    Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000868-42 Sponsor Protocol Number: B3461045 Start Date*: 2016-09-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005709-50 Sponsor Protocol Number: 1122005 Start Date*: 2006-05-05
    Sponsor Name:Cardiology, University of Frankfurt
    Full Title: Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells in patients with chronic ischemic heart disease
    Medical condition: Patients with ischemic coronary artery disease (congestive heart failure) and s/p anterior myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:41:44 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA